– Pathological criteria so far employed in the prognosis of renal cell carcinoma provide no clinically useful information. This paper emphasises the possibilities offered by histopathology today for tackling this clinical problem more effectively. Nuclear analysis, with objective and quantitative evaluation of the degree of distortion, may provide extremely useful information. The authors correctly classified 90% of the 50 cases of renal cell carcinoma considered and whose follow-up at 5 years was known.
AlexandreL., VieillefondA., BenoitG., YatagheneY., BensadounH., BlanchetP., JardinA.: Cancer of the kidney, prognostic value of nuclear grading for the early diagnosis of metastasis. Presse Med., 23: 699–701, 1994.
2.
Artacho-PérulaE., Roldan-VillalobosR., Martinez-CuevasJ. Fv, Lopez-RubioF.: Nuclear quantitative grading by discriminant analysis of renal cell carcinoma samples. A patient survival evaluation. Clin. Pathol., 173: 105–114, 1994.
3.
Artacho-PérulaE., Roldan-VillalobosR., Martinez-CuevasJ.F.: Value of volume weighted mean nuclear volume in grading and prognosis of renal cell carcinoma. J. Clin. Pathol., 47: 324–328, 1994.
4.
AuerG.U., CasperssonT.O., WaligreenA.S.: DNA content and survival in mammary carcinoma. Analyt. Quant. Cytol., 3: 161–165, 1980.
5.
BaakJ.P.A.: Manual of quantitative pathology in cancer diagnosis and prognosis. Berlin-Heidelberg, Springer Verlag, 1991.
6.
BaillyM., BainC., FavrotM.C., OzturkM.: Somatic mutations of von Hippel-Lindau (VHL) tumour suppressor gene in European kidney cancers. Int. J. Cancer, 63: 660–664, 1995.
7.
BarthP.J., SiebelA., GerharzE., KohlerH.H.: Nuclear morphometry of renal cell carcinomas. Gen. Diagn. Pathol., 141: 29–33, 1995.
8.
BernhardH., KarbachJ., WolfelT., BuschP., StorkelS., StockleM., WolfelC., SeligerB., HuberC., Meyerzum-BuschenfeldeK.H.: Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocytes (CTL) clones. Int. J. Cancer, 59: 837–842.
BlarneyR.: Does biological understanding influence surgical practice?Br. J. Cancer, 60: 271–274, 1989.
11.
BodianC.A., PerzinK.H., LattesR., HoffmannP., AbernathyT.G.: Prognostic significance of benign proliferative breast disease. Cancer, 71: 3896–907, 1993.
12.
BodianC.A., PerzinK.H., LattesR., HoffmannP.: Reproducibility and validity of pathologic classification of benign breast disease and implication for clinical applications. Cancer, 71: 3908–13, 1993.
13.
BolhuisR.L., WeijtensE.M., WillemsenR.A., ValerioD.: Functional expression of a single chain FV/gamma receptor with renal cell carcinoma specificity in activated human PBL (Meeting abstract). J. Cell. Biochem., suppl. 21A: 418, 1995.
14.
BosniakM.A., BirnbaumB.A., KrinskyG.A., WaismanJ.: Small renal parenchimal neoplasms: further observation on growth. Radiology, 197: 589–587, 1995.
15.
BosniakM.A.: Observation of small incidentally detected renal masses. Semin. Urol. Oncol., 3: 267–272, 1995.
16.
BretheauD., LechevallierE., de FromontM., SaultM.C., RampaiM., CoulangeC.: Prognostic value of nuclear grade of renal cell carcinoma. Cancer, 76: 2543–2549, 1995.
17.
BrugalG.: Interpretation of proliferation markers. In: Compendium on the cytology and histology laboratory. WiedG.L., BartelsP.H., RosenthalD.L., SchenkU. (eds). Tutorials of cytology, Chicago: 234–240, 1994.
18.
BurkeH.B., HensonD.E.: The American Joint Committee on Cancer. Criteria for prognostic factors and for an enhanced prognostic system. Cancer72: 3131–3135, 1993.
19.
CarducciM., PiantadosiS., SimkinT., EpsteinJ., MarshallF., SimonsJ., PartinA.: Nuclear morphometry correctly identifies patients with early stage renal cell carcinomas at high risk for relapse after nephrectomy as candidates for adjuvant therapy (meeting abstract). Proc. Ann. Meet. Am. Soc. Clin. Oncol., 14: A647, 1995.
20.
CavazzanaA.O., Prayer-GalettiT., SangiorgioA., FassinaA.S., PanozzoM., ZucchettaP., PaganoF.: DNA content, nuclear grading and early tumour progression in renal cell cancer: a prospective study on frozen specimens. Eur. Urol., 22: 311–315, 1992.
21.
ChenF., KishidaT., DuhF.M., RenbaumP., OrcuttM.L., SchmidtL., ZbarB.: Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumour suppressor gene. Cancer Res., 55: 4804–4807, 1995.
22.
ChengW.S., FarrowG.M., ZinckeH.: The incidence of multicentricity in renal cell carcinoma. J. Urol., 146: 1221–1223, 1991.
23.
CrockerJ., MacartneyJ.C., SmithP.J.: Correlation between DNA flow cytometric and nucleolar organizer region data in non-Hodgkin's lymphomas. J. Pathol., 154: 151–156, 1988.
24.
CroninK.J., WilliamsN.N., KerinM.J., CreaghT.A., DervanP.A., SmithJ.M., FitzpatrickJ.M.: Proliferating cell nuclear antigen: a new prognostic indicator in renal cell carcinoma. J. Urol., 152: 834–836, 1994.
25.
Dal CinP., GaetaJ., HubenR., LiF.P., ProutG.R.Jr., SandbergA.A.: Renal cortical tumours. Am. J. Clin. Pathol., 134: 27–34, 1989.
26.
De RieseW.T., CrabtreeW.N., AllhoffE.P., WernerM., LiedkeS., LenisG., AtzpodienJ., KirchnerH.: Prognostic significance of Ki67 immunostaining in nonmetastatic renal cell carcinoma. J. Clin. Oncol., 11: 1804–1808, 1993.
27.
DelahuntB., BeckerR.L., BethwaiteP.B., RibasJ.L.: Computerized nuclear morphometry and survival in renal cell carcinoma: comparison with other prognostic indicators. Pathology, 26: 353–358, 1994.
28.
DelahuntB., BethwaiteP.B., NaceyJ.N., RibasJ.L.: Proliferating cell nuclear antigen (PCNA) expression as a prognostic indicator for renal cell carcinoma: comparison with tumour grade, mitotic index and silver staining nucleolar organizer region numbers. J. Pathol., 170: 471–477, 1993.
29.
DelahuntB., BethwaiteP.B., ThorntonA., RibasJ.L.: Proliferation of renal cell carcinoma assessed by fixation-resistant polyclonal Ki67 antibody labeling. Correlation with clinical outcome. Cancer, 75: 2714–2719, 1995.
30.
DerenziniM., PessionA., TrereD.: Quantity of nucleolar silver-stained proteins is related to proliferating activity in cancer cells. Lab. Invest., 63: 137–140, 1989.
31.
Di SilverioF., GallucciM., FlammiaG.P., De VicoA., CaponeraM., EleuteriP., ForteD., CavalloD., De VitaR.: Biological and clinical implication of cellular DNA content in renal cell carcinomas. Eur. Urol., 21 (suppl. 1): 43–47, 1992.
32.
DonhuijsenK., SchulzS., LederL.D.: Nuclear grading of renal carcinoma is morphometry necessary?J. Cancer Res. Clin. Oncol., 117: 73–78, 1991.
33.
El-NaggarA.K., HurrK., TuZ.N., TuckerS.L., SwansonD., HsuP.H.: Interphase cytogenetics of renal cortical neoplasms. Correlation with DNA ploidy by flow cytometry. Am. J. Clin. Pathol., 104: 141–149, 1995.
34.
EschwegeP., SaussineC., SteichenG., DelepaulB., DrelonI., JacqminD.: Radical nephrectomy for renal cell carcinoma 30 mm or less: long-term follow-up results. J. Urol., 155: 1196–1199, 1996.
35.
EskelinenM., LipponenP., NordlingS.: Prognostic evaluation of DNA flow cytometry and histo-morphological criteria in renal cell carcinoma. Anticancer Res., 15: 2279–2284, 1995.
36.
EvansH.J., BucklandR.A., PardueM.L.: Location of genes coding for 18S and 28S ribosomal RNA in the human genome. Chromosoma, 48: 405–426, 1974.
37.
FieldD.H., FitzgeraldP.H., SynF.Y.T.: Nucleolar silver-staining pattern related to cell cycle phase and cell generation of PHA-stimulated human lymphocytes. Cytobios., 41: 23–33, 1984.
38.
FlintA., GrossmanH.B., LiebertM., LloydR.W., BrombergJ.: DNA and PCNA content of renal cell carcinoma and prognosis. Am. J. Clin. Pathol., 103: 14–19, 1995.
FuhrmanS.A., LaskyL.C., LimasC.: Prognostic significance of morphologic parameters in renal cell carcinoma. Am. J. Surg. Pathol., 6: 655–663, 1982.
41.
FujiokaT., HasegawaM., OgiuK., MatsushitaY., SatoM., KuboT.: Antitumour: effects of angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) against murine renal cell carcinoma. J. Urol., 155: 1775–1778, 1996.
42.
GelbA.B., ShibuyaR.B., WeissL.M., MedeirosL.J.: Stage I renal cell carcinoma. A clinicopathologic study of 82 cases. Am. J. Surg. Pathol., 17: 275–286, 1993.
43.
GnarraJ.R., LermanM.I., ZbarB., LinehanW.M.: Genetics of renal cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Seminars in Oncology, 22: 3–8, 1995.
44.
GoessensG., ThiryM., LepointA.: Relation between nucleoli and nucleolus-organizing regions during the cell cycle. In: StahlA., LucianiJ.M., Vagner-CapodanaA.M. (eds.). Chromosomes today. London, Allen & Unwin, 9: 261–271, 1987.
45.
GolumbeckP., LevitskyH., JaffeeL., PardollD.M.: The antitumour response as a problem of self-nonself discrimination: implications for immunotherapy. Immunol. Res., 12: 183–192, 1993.
46.
GoodpastureC., BloomS.E.: Visualization of nucleolar organizer regions in mammalian chromosomes using silver staining. Chromosoma, 53: 37–50, 1974.
47.
GriffioenA.W., DamenC.A., MartinottiS., BlijhamG.H., GroenewegenG.: Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer, Res., 56: 1111–1117, 1996.
48.
GrignonD.J., Abdel-MalakM., MertensW., KosterJ., KeeneyM., SakrW., ShepherdR.R.: Prognostic significance of cellular proliferation in renal cell carcinoma: a comparison of synthesis-phase fraction and proliferating cell nuclear antigen index. Modern Pathol., 8: 18–24, 1995.
49.
GuinanP., SaffrinR., StuhldreherD., FrankW., RubensteinM.: Renal cell carcinoma comparison of the TNM and Robson stage groupings. J. Surg. Oncol., 59: 186–189, 1995.
50.
HallP.A., CrockerJ., WattsA., StanfeldA.G.: A comparison of nucleolar organizer region staining and Ki67 immuno-staining in non-Hodgkin's lymphomas. Histopathology, 12: 373–381, 1988.
51.
HansenA.B., AndersenC.B.: Role of intercellular adhesion molecule-1 (ICAM-1) and lymphocyte function associated antigen-1 (LFA1) in peripheral blood mononuclear cell activation by human renal carcinoma cells. Urol. Res., 22: 309–315, 1994.
52.
HelpapB.: Grading and prognostic significance of urologic carcinomas. Urol. Int., 48: 245–257, 1992.
53.
HendersonA.A., WarburtonD., AtwoodK.C.: Location of ribosomal DNA in the human chromosome complement. Proc. Natl. Acad. Sci. USA, 169: 3394–3398, 1972.
54.
HofmockelG., TsatalpasP., MullerH., DammrichJ., PootM., Maurer-SchultzeB., Muller-HermelinkH.K., FrohmullerH.G., BassukasI.D.: Significance of conventional and new prognostic factors for locally confined renal cell carcinoma. Cancer, 76: 296–306, 1995.
55.
HowellW.M.: Visualization of ribosomal gene activity: silver stains proteins associated with rRNA transcribed from oocyte chromosomes. Chromosoma, 62: 361–367, 1977.
56.
ItataniH., TsujihataM.: Diagnosis and therapy of incidental renal cell carcinoma. Hinyokika Kiyo, 41:719–723, 1995.
57.
IwanumaY., KatoK., YagitaH., OkumuraK.: Induction of tumour-specific cytotoxic T lymphocytes and natural killer cells by tumour cells transfected with the Interleukin-2 gene. Cancer Immunol. Immunother., 40: 17–23, 1995.
58.
Jan-MohamedR.M., ArmstrongS.J., CrockerJ., LylandM.J., HultenM.A.: The relationship between number of interphase NORs and NOR-bearing chromosomes in non-Hodgkin's lymphomas. J. Pathol., 154: 151–156, 1988.
59.
JochumW., SchroderS., al TahaR., AugustC., GrossA.J., BergerJ., PadbergB.C.: Prognostic significance of nuclear DNA content and proliferative activity in renal cell carcinomas. A clinicopathologic study of 58 patients using mitotic count, MIB-1 staining, and DNA cytophotometry. Cancer, 77: 514–521, 1996.
60.
KohlerH.H., BarthP.J., SiebelA., GerharzE.W., BittingerA.: Quantitative assessment of vascular surface density in renal cell carcinomas. Br. J. Urol., 77: 650–654, 1996.
KovacsG.: Papillary renal cell carcinoma: a morphologic and cytogenetic study of 11 cases. Am. J. Pathol., 134: 27–34, 1989.
64.
KovacsG.: The value of molecular genetic analysis in the diagnosis and prognosis of renal cell tumours. World J. Urol., 12: 64–68, 1994.
65.
KriegmairM., ObernederR.: Tumour cell vaccination for treatment of renal cell carcinoma. Urologe A, 34: 204–207, 1995.
66.
KurozumiT., YagiH., OmotoT., IwataY.: Extracapsular tumour invasion in renal cell carcinoma: with special reference to limitation of surgical enucleation. Nippon Hinyokika Gakkai Zasshi, 84: 1943–1947, 1993.
67.
LabudaT., LandoP., BjorkdahlO., KallandT., VessellaR., HedlundG., ErikssonG., SjogrenH.O., DohlstenM.: A novel co-stimulatory T cell antigen co-expressed on renal cell carcinoma. Int. Immunol., 7: 1425–1432, 1995.
68.
LarssonP., RoosJ., StenlingR., LjungbergB.: Tumour-cell proliferation and prognosis in renal cell carcinoma. Int. J. Cancer, 55: 566–570, 1993.
69.
LernerS.E., HawkinsC.A., BiuteM.L., GrabnerA., WollanP.C., EickholtJ.T., ZinckeH.: Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J. Urol, 155: 1868–1873, 1996.
70.
LinehanW.M.: The VHL tumour suppressor gene: its role in hereditary and sporadic renal carcinoma (meeting abstract). Proc. Ann. Meet. Am. Assoc. Cancer Res., 736: A667–668, 1995.
71.
LissoniP., BarniS., AndresM., ScardinoE., VigoreL., VezzoR., RescaldaniR., TanciniG.: Lymphocytosis decline is not responsible for tumour progression in cancer patients chronically treated with Interleukin-2. Tumori, 80: 283–285, 1994.
72.
MacLennanG.T., BostwickD.G.: Microvessel density in renal cell carcinoma: lack of prognostic significance. Urology, 46: 27–30, 1995.
73.
MaeurerM.J., MartinD.M., CastelliC., ElderE., LederG., StorkusW.J., LotzeM.T.: Host immune response in renal cell cancer: Interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumour-infiltrating lymphocytes. Cancer Immunol. Immunother., 41: 111–121, 1995.
74.
MaldazysJ.D., de KernionJ.B.: Prognostic factors in metastatic renal cell carcinoma. J. Urol., 136: 376–381, 1986.
75.
MariuzziG.M., MariuzziL., MombelloA., SantinelliA.: Grading and prognosis of tumours. In: Compendium on the computerized cytology and histology laboratory. WiedG.L., BattelsP.H., RosenthalD.L, SchenckU. (eds.): Tutorials of cytology. Chicago, 68–88, 1994.
76.
MariuzziG.M., MambelliV., CrianteP., SistiS.: Quantitative evaluation of morphological parameters for infiltrating ductal breast cancer prognosis. Pathol. Res., Pract., 185: 698–700, 1989.
77.
MariuzziG.M., MariuzziL., MombelloA., SantinelliA., ValliM., RahalD., ThompsonD., BartelsP.H.: Quantitative study of ductal breast cancer progression: a progression index (PI) for premalignant lesions and in situ carcinoma. Pathol. Res. Pract., 192: 428–436, 1996.
78.
MariuzziG.M., MariuzziL., MombelloA., SantinelliA., ValliM., RahalD., ThompsonD., BartelsP.H.: Quantitative study of ductal breast cancer progression: morphometric evaluation of phenotypical changes occurring in benign and preinvasive epithelial lesions. Pathol. Res Pract., 190: 1056–1065, 1994.
79.
MariuzziG.M., SistiS.: Multivariate quantitative histopathological assessment of prognostic factors in ductal infiltrating breast carcinoma. In Vivo, 7: 357–362, 1993.
80.
MariuzziG.M., SistiS., SantinelliA., ValliM., MariuzziL.: Evolutionary somatic cell changes in cervical tumour progression quantitatively evaluated with morphological, histochemical and kinetic parameters. Pathol. Res. Pract., 188: 454–460, 1992.
MitropoulosD., AlamanisC., DeliveliotisC., ZervasA., TzirakisA., DimopuolosC.: T lymphocytes subsets in the peripheral blood of patients with renal cell carcinoma. Acta Urol. Belg., 63: 21–25, 1995.
84.
MontieJ.E.: Prognostic factors for renal cell carcinoma (editorial). J. Urol., 152: 1397–1398, 1994.
85.
MoritaT., ShinoharaN., TokueA.: Antitumour effect of a synthetic analogue of fumagillin on murine renal carcinoma. Br. J. Urol., 74: 416–421, 1994.
86.
MukamelE., KonichezkyM., EngelsteinD., ServadioC.: Incidental small renal tumours accompanying clinically overt renal cell carcinoma. J. Urol., 140: 22–24, 1988.
87.
MurphyG.F., PartinA.W., MaygardenS.J., MohlerJ.L.: Nuclear shape analysis for assessment of prognosis in renal cell carcinoma. J. Urol., 143: 1103–1107, 1990.
88.
MurphyW.M., BeckwithJ.B., FarrowG.M.: AFIP Atlas of tumour pathology. Tumours of the kidney, bladder and related urinary structures. Published by the Armed Force Institute of Pathology, Washington DC, 1994.
89.
MussH.B.: The use of interferon in renal cell carcinoma. Eur. J. Cancer, 27: 84–87, 1991.
90.
NativO., SaboE., RavivG., MedaliaO., MoskovitzB., GoldwasserB.: The role of nuclear morphometry for predicting disease outcome in patients with localized renal cell carcinoma. Cancer, 76: 1440–1444, 1995.
91.
OhmoriT., OkadaK., AritaM., WatanabeY., MiyazakiT., TabeiR.: Characteristics of MHC antigen expression and tumour infiltrating mononuclear cells in renal cell adenomas and carcinomas. Histol. Histopathol., 10: 789–794, 1995.
92.
OyaM., NakamuraK., BabaS., HataJ.I., TazakiH.: Intrarenal satellites of renal cell carcinoma: histopathologic manifestation and clinical implication. Urology, 46: 161–164, 1995.
93.
PageD.L., DupontW.D.: Anatomic markers of human premalignancy and risk of breast cancer. Cancer J., 66: 1326–35, 1990.
94.
PageD.L., DupontW.D.: Benign breast disease: indicator of increased breast cancer risk. Cancer Detec. Prevent., 16: 93–7, 1992.
95.
PageD.L., RogersL.W.: Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum. Pathol., 10: 1095–7, 1992.
96.
PageD.L.: Cancer risk assessment in benign breast biopsies. Hum. Pathol., 17: 871–4, 1986.
97.
PapadopoulosI., Weichert-JacobsenK., NurnbergN., SprengerE.: Quantitative DNA analysis in renal cell carcinoma. Comparison of flow and image cytometry. Anal. Quant. Cytol. Histol., 17: 272–275, 1995.
98.
PapadopoulosI., Weichert-JacobsenK., SprengerE., WackerH.H.: DNA content and proliferation marker Ki67 as prognostic indicators in renal cell carcinoma. Urol. Int., 53: 181–185, 1994.
99.
PomerS., ThieleR., StaehlerG., DrehmerI., LohrkeH., SchirrmacherV.: Tumour vaccination in renal cell carcinoma with and without Interleukin-2 (IL-2) as adjuvant a clinical contribution to the development of effective active specific immunization. Urologe A, 34: 215–220, 1995.
RadmayrC., BockG., HobischA., KlockerH., BartschG., ThurnherM.: Dendritic antigen presenting cells from the peripheral blood of renal cell carcinoma patients. Int. J. Cancer, 63: 627–632, 1995.
102.
RadmayrC., KlockerH., HobischA., BockG., BartschG., ThurnherM.: B7-expression on cultured T cells from renal cell carcinoma (meeting abstract). Proc. Ann. Meet. Am. Assoc. Cancer Res., 36: A2858, 1995.
103.
RosaJ., MethaA., FilipM.I.: Nucleolar organizer regions, proliferative activity and DNA index in gastric carcinoma. Histopathology, 16: 614–616, 1990.
104.
RosaiJ.: Borderline epithelial lesions of the breast. Am. J. Surg. Pathol., 15: 209–21, 1991.
105.
RosenP.P.: Proliferative breast “disease”. An unresolved diagnostic dilemma. Cancer, 71: 3798–806, 1993.
106.
RuizJ.L., HernandezM., MartinezJ., VeraC., Jimenez-CruzJ.F.: Value of morphometry as an independent prognostic factor in renal cell carcinoma. Eur. Urol., 27: 54–57, 1995.
107.
Ruiz-CerdaJ.L., HernandezM., GomisF., VeraC.D., KimlerB.F., O'ConnorJ.E., Jimenez-CruzF.: Value of the deoxyribonucleic acid ploidy and nuclear morphometry for prediction of disease progression in renal cell carcinoma. J. Urol., 155: 459–465, 1996.
108.
SandockD.S., SeftelA.D., ResnickM.I.: A new protocol for the follow-up of renal cell carcinoma based on the pathological stage. J. Urol., 154: 28–31, 1995.
109.
SatoK., KatoT.: Cancer therapy targeting tumour-induced neovascularization. Gan To Kagaku Ryoho, 21: 295–300, 1994.
110.
SatoK., TeradaK., SugiyamaT., TakahashiS., SaitoM., MoriyamaM., KakinumaH., SuzukiY., KatoM., KatoT.: Frequent overexpression of vascular endothelial growth factor gene in human renal cell carcinoma. Tohoku J. Exp. Med., 173: 355–360, 1994.
111.
SchnittS.J., ConnollyJ.L., TavassoliF.A., FechnerR.E., KempsonR.L., GelmannR., PageD.L.: Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardised criteria. Am. J. Surg. Pathol., 16: 1133–43, 1992.
112.
ShimazuiT., TomobeM., HattoriK., UchidaK., AkazaH., KoisoK.: A prognostic significance of nucleolar organizer region (AgNOR) in renal cell carcinoma. J. Urol., 154: 1522–1526, 1995.
113.
SistiS., SantinelliA., ValliM., TaborroR., MannelloB., MariuzziG.M.: Quantitative methods in histopathology: evaluation of their prognostic power in infiltrating ductal breast carcinoma. Acta Stereol., 11: 79–88, 1992.
114.
SteinbachF., StockleM., GriesingerA., StorkelS., SteinR., MillerD.P., HohenfellnerR.: Multifocal renal cell tumours: a retrospective analysis of 56 patients treated with radical nephrectomy. J. Urol., 152: 1393–1396, 1994.
115.
SteinbachF., TanabeK., AlexanderJ., EdingerM., TubbsR., BrennerW., StockleM., NovickA.C., KleinE.A.: The influence of cytokines on the adhesion of renal cancer cells to endothelium. J. Urol., 155: 743–748, 1996.
116.
StockleM., StorkelS., MielkeR., SteinbachF., el-DamanhouryH., VogesG., HohenfellnerR.: Characterization of conservatively resected renal tumour using automated image analysis DNA cytometry. Cancer, 68: 1926–1931, 1991.
117.
SuzukiY., TamuraG., SakataK., MaesawaC., FujiokaT., SatodateR.: Mutation of the von Hippel-Lindau disease gene in human renal cell carcinoma (meeting abstract). Proc. Ann. Meet. Am. Assoc. Cancer Res., 36: A3480, 1995.
118.
TakahashiA., SasakiH., KimS.J., TobisuK., KakizoeT., TsukamotoT., KumamotoY., SugimuraT., TeradaM.: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res., 54: 4233–4237, 1994.
119.
TakamizawaA.: Nuclear morphometry and DNA content in grading of renal cell carcinoma. Nippon Hinyokika Gakkai Zasshi, 79: 1054–1062, 1988.
120.
TakashiM., NakanoY., SakataT., MiyakeK., HamajimaN.: Multivariate evaluation of prognostic determinants for renal cell carcinoma. Urol. Int., 50: 6–12, 1993.
121.
TakashiM., TakagiY., SakataT., ShimojiT., MiyakeK.: Clinicopathological characteristics of small renal cell carcinomas. Int. Urol. Nephrol., 26: 621–629, 1994.
122.
TargonskiP.V., FrankW., StuhldreherD., GuinanP.D.: Value of tumour size in predicting survival from renal cell carcinoma among tumours nodes and metastases stage 1 and stage 2 patients. J. Urol., 152: 1389–1392, 1994.
123.
TartourE., LatourS., MathiotC., ThiounnN., MosseriV., JoyeuxI., D'EnghienC.D., LeeR., DebreB., FridmanW.H.: Variable expression of CD3-zeta chain in tumor infiltrating lymphocytes (TIL) derived from renal cell carcinoma: relationship with TIL phenotype and function. Int. J. Cancer, 63: 205–212, 1995.
124.
ThrasherJ.D., PaulsonD.F.: Prognostic factors in renal cancer. Urol. Clin. North Am., 20: 247–262, 1993.
125.
ThurnerM., RadmayrC., HobischA., BockG., RomaniN., BartschG., KlockerH.: Tumour infiltrating T lymphocytes from renal cell carcinoma express B7-1 (CD80): T-cell expansion by T-T cell co-stimulation. Int. J. Cancer, 62: 559–564, 1995.
126.
TongaonkarH.B., DandekarN.P., DalaiA.V., KulkarniJ.N., KamatM.R.: Renal cell carcinoma extending to the renal vein and inferior vena cava: results of surgical treatment and prognostic factors. J. Surg. Oncol., 59: 94–100, 1995.
127.
TosiP., LuziP., BaakJ.P.A., MiraccoC., SantopietroR., VindigniC., MatteiF.M., AcconciaA., MassaiM.R.: Nuclear morphometry as an important prognostic factor in stage I renal cell carcinoma. Cancer, 58: 2512–2518, 1986.
128.
TrereD., PessionA., DerenziniM.: The silver stained proteins of intraphasic nucleolar organizer regions as a parameter of cell duplication rate. Exp. Cell., Res., 184: 131–137, 1989.
129.
TsukamotoT.: Invasion, metastasis and angiogenesis of renal cell carcinoma. Nippon Hinyokika Gakkai Zasshi, 87: 1–12, 1996.
130.
Van der PoelH.G., MuldersP.F.A., OosterhofG.O.N., SchaafsmaH.E., HendriksJ.C.M., SchalkenJ.A., DebruyneF.M.J.: Prognostic value of kariometric and clinical characteristics in renal cell carcinoma. Quantitative assessment of tumour heterogeneity. Cancer, 72: 2667–2674, 1993.
131.
WangQ., RedovanC., TubbsR., NovickA., KudohS., FinkeJ., BukowskiR.M.: Interleukin 10 (IL-10) gene expression and production by human renal cell carcinoma (RCC): possible origin from tumour infiltrating mononuclear cells (meeting abstract). Proc. Ann. Meet. Am. Assoc. Cancer Res., 14: A2775, 1995.
WenderothU.K., GerlachB., KoppenA., HautmannR.E.: Computerized nuclear morphometry: prognostic value for carcinoma of the prostate and renal cell carcinoma. Investig. Urol. (Berl.), 5: 16–19, 1994.
134.
YoshinoS., KatoM., OkadaK.: Prognostic significance of microvessel count in low stage renal cell carcinoma. Int. Urol., 2: 156–160, 1995.
135.
ZeaA.H., GhoshP., LongoD.L., StroblS.L., OchoaA.C.: Loss of Th1 phenotype in peripheral blood T cell (PBL-T) from patients with renal cell carcinoma (meeting abstract). Proc. Ann. Meet. Am. Assoc. Cancer Res., 14: A2755, 1995.
